ReviewPsoriasis (Auckland, N.Z.)2023
Palmoplantar Pustulosis: A Systematic Review of Risk Factors and Therapies.
Review in Psoriasis (Auckland, N.Z.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Efficacy and safety of Janus kinase and TYK2 inhibitors in the treatment of generalized pustular psoriasis and palmoplantar pustulosis: a systematic review.Immunologic research · 2026Pooled it
- Ethnic Differences of Palmoplantar Pustulosis: A Systematic Review.American journal of clinical dermatology · 2025Pooled it
- Upadacitinib Versus Acitretin for the Resolution of Pustules in Palmoplantar Pustulosis During Acute Phase: A Single-Center, Open-Label Prospective Cohort Study.American journal of clinical dermatology · 2025Trial
- Palmoplantar pustulosis: pathogenesis, differential diagnosis, and treatment.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Review
- Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature.Health science reports · 2026Review
- [Inflammatory dermatosis in adult chronic non-bacterial osteomyelitis (adult CNO) from a dermatological perspective].Zeitschrift fur Rheumatologie · 2026Article
- Bimekizumab plus topical photochemotherapy effective in palmoplantar pustulosis in a patient with hidradenitis suppurativa.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Article
- The Relative Efficacy of Monotherapies for Palmoplantar Pustulosis and Palmoplantar Psoriasis: A Network Meta-Analysis Study of the Palmoplantar Spectrum.Medicina (Kaunas, Lithuania) · 2026Review
- Case Report: Abrocitinib treatment for refractory palmoplantar pustulosis.Frontiers in medicine · 2026Article
- From apremilast to JAK inhibitors-salvage treatment strategies for refractory palmoplantar pustulosis: case series.Frontiers in medicine · 2026Article
- Targeting the JAK/STAT pathway in palmoplantar pustulosis: a review.Annals of medicine · 2025Review
- Effectiveness and Safety of Delgocitinib Cream in Pustulosis Palmoplantaris: A Case Series.Acta dermato-venereologica · 2025Article
- Psoriasis in the Context of Dermatologic Disorders: A Comprehensive Overview.Diseases (Basel, Switzerland) · 2025Review
- Disease features, treatments, and burden of palmoplantar pustulosis in Korea: The EPPPIK study.The Journal of dermatology · 2025Article
- Palmoplantar Pustulosis as an Immune-Mediated Inflammatory Disease with a Possible Relevance of Th17 Cell Plasticity: A Narrative Review.Dermatology and therapy · 2025Review
- Onychoscopy in Palmoplantar Psoriasis: A Comparative Study of Nonpustular Palmoplantar Psoriasis and Palmoplantar Pustulosis.Dermatology practical & conceptual · 2024Article
- Combination of secukinumab and acitretin for generalized pustular psoriasis: A case report and review of literature.The Journal of international medical research · 2024Review
- Skin Symptoms That Appeared after Fixation with a Titanium Plate in a Jaw Deformity Patient Suffering from Palmoplantar Pustulosis: A Case Report.Dentistry journal · 2023Article
- Hypopyon Sign in Acral Lesions: Dermoscopic Findings of a Patient with Palmoplantar Pustulosis.Current health sciences journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Palmoplantar pustulosis (PPP) is a chronic, relapsing, inflammatory disease that can occur alone or in association with arthritis. There is still controversy about whether it should be separated from psoriasis or classified as pustular psoriasis. Furthermore, drug-induced paradoxical PPP is a special variant of PPP that differs from classic PPP in several ways. Treatment of PPP is still challenging, and there are a number of treatment-resistant cases. This review summarizes the risk factors for the development of PPP and the currently available treatment modalities. Female sex, smokers or ex-smokers, obesity, thyroid dysfunction, and treatment with a tumor necrosis factor (TNF)-α inhibitor have been identified as risk factors for the disease's development, severity, and course. Topical treatments and phototherapy are effective for some patients and are used as a first-line or adjuvant treatment modality. Conventional treatments including retinoids and fumaric acid show good effects and can increase the efficacy of treatment with psoralen + ultraviolet light therapy (PUVA). Ciclosporin is fast acting, but relapse mostly occurs immediately after cessation. TNF-α inhibitors are efficient, and an even better response can be achieved with IL-17 and IL-23 blockers as well as apremilast. The effect of Janus kinase inhibitors seems to be promising according to case reports, but further investigations with larger cohorts are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.